TDM in MMT
- Conditions
- Opiod dependenceMental Health - Addiction
- Registration Number
- ACTRN12606000033549
- Lead Sponsor
- The Langton Centre
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 90
Agree to and be capable of signing an informed consent form.In treatment at least 2 monthsOn a stable methadone dose for at least 4 weeksOn a methadone dose greater than or equal to 50mg/dayUse heroin 4 times or more in the last monthCurrent methadone prescriber consents to subject's participation in the research.
Considered unwilling, unable or unlikely to comply with the study protocolPregnant or breast feedingUsing drugs and dietary components known to interact with methadone pharmacokinetics (including antipsychotics, fluvoxamine, St John's Wort, Grapefruit juice)Unstable medical conditions (liver disease with jaundico/ascites/encephalopathy, structural heart disease, psychosis.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Heroin use[At 3 and 6 months]
- Secondary Outcome Measures
Name Time Method Plasma R- and S- methadone concentrations[At 3 and 6 months.]